These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

442 related articles for article (PubMed ID: 16101667)

  • 1. Not all statins interfere with clopidogrel during antiplatelet therapy.
    Mach F; Senouf D; Fontana P; Boehlen F; Reber G; Daali Y; de Moerloose P; Sigwart U
    Eur J Clin Invest; 2005 Aug; 35(8):476-81. PubMed ID: 16101667
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple antiplatelet effects of clopidogrel are not modulated by statin type in patients undergoing percutaneous coronary intervention.
    Smith SM; Judge HM; Peters G; Storey RF
    Platelets; 2004 Dec; 15(8):465-74. PubMed ID: 15763887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of statin treatment on platelet inhibition by clopidogrel - a randomized comparison of rosuvastatin, atorvastatin and simvastatin co-treatment.
    Malmström RE; Ostergren J; Jørgensen L; Hjemdahl P;
    J Intern Med; 2009 Nov; 266(5):457-66. PubMed ID: 19549094
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atorvastatin does not affect the antiplatelet potency of clopidogrel when it is administered concomitantly for 5 weeks in patients with acute coronary syndromes.
    Mitsios JV; Papathanasiou AI; Rodis FI; Elisaf M; Goudevenos JA; Tselepis AD
    Circulation; 2004 Mar; 109(11):1335-8. PubMed ID: 15023882
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of atorvastatin and pravastatin on platelet inhibition by aspirin and clopidogrel treatment in patients with coronary stent thrombosis.
    Wenaweser P; Windecker S; Billinger M; Cook S; Togni M; Meier B; Haeberli A; Hess OM
    Am J Cardiol; 2007 Feb; 99(3):353-6. PubMed ID: 17261397
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
    Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Absence of interaction between atorvastatin or other statins and clopidogrel: results from the interaction study.
    Serebruany VL; Midei MG; Malinin AI; Oshrine BR; Lowry DR; Sane DC; Tanguay JF; Steinhubl SR; Berger PB; O'Connor CM; Hennekens CH
    Arch Intern Med; 2004 Oct; 164(18):2051-7. PubMed ID: 15477442
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A randomised determination of the Effect of Fluvastatin and Atorvastatin on top of dual antiplatelet treatment on platelet aggregation after implantation of coronary drug-eluting stents. The EFA-Trial.
    Wenaweser P; Eshtehardi P; Abrecht L; Zwahlen M; Schmidlin K; Windecker S; Meier B; Haeberli A; Hess OM
    Thromb Haemost; 2010 Sep; 104(3):554-62. PubMed ID: 20664903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of statins on platelet inhibition by a high loading dose of clopidogrel.
    Müller I; Besta F; Schulz C; Li Z; Massberg S; Gawaz M
    Circulation; 2003 Nov; 108(18):2195-7. PubMed ID: 14568892
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of clopidogrel on the steady-state pharmacokinetics of fluvastatin.
    Ayalasomayajula SP; Vaidyanathan S; Kemp C; Prasad P; Balch A; Dole WP
    J Clin Pharmacol; 2007 May; 47(5):613-9. PubMed ID: 17442686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The inhibitory potency of clopidogrel on ADP-induced platelet activation is not attenuated when it is co-administered with atorvastatin (20 mg/day) for 5 weeks in patients with acute coronary syndromes.
    Mitsios JV; Papathanasiou AI; Elisaf M; Goudevenos JA; Tselepis AD
    Platelets; 2005 Aug; 16(5):287-92. PubMed ID: 16011979
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The antiplatelet effect of clopidogrel is not attenuated by statin treatment in stable patients with ischemic heart disease.
    Vinholt P; Poulsen TS; Korsholm L; Kristensen SR; Hallas J; Damkier P; Mickley H
    Thromb Haemost; 2005 Aug; 94(2):438-43. PubMed ID: 16113837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accelerated platelet inhibition by switching from atorvastatin to a non-CYP3A4-metabolized statin in patients with high platelet reactivity (ACCEL-STATIN) study.
    Park Y; Jeong YH; Tantry US; Ahn JH; Kwon TJ; Park JR; Hwang SJ; Gho EH; Bliden KP; Kwak CH; Hwang JY; Kim S; Gurbel PA
    Eur Heart J; 2012 Sep; 33(17):2151-62. PubMed ID: 22507978
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pravastatin and simvastatin improves acetylsalicylic acid-mediated in vitro blood platelet inhibition.
    Luzak B; Rywaniak J; Stanczyk L; Watala C
    Eur J Clin Invest; 2012 Aug; 42(8):864-72. PubMed ID: 22409214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The antiplatelet effect of atorvastatin in patients with acute coronary syndrome depends on the hs-CRP level.
    Vasilieva E; Kasyanova O; Shpektor A
    Acute Card Care; 2008; 10(3):181-4. PubMed ID: 18608041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of switching statins on lipid and apolipoprotein ratios in the MERCURY I study.
    Cheung RC; Morrell JM; Kallend D; Watkins C; Schuster H
    Int J Cardiol; 2005 Apr; 100(2):309-16. PubMed ID: 15823640
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of five HMG-CoA reductase inhibitors-- atorvastatin, lovastatin, pravastatin, rosuvastatin and simvastatin: pharmacological, pharmacokinetic and analytical overview and development of a new method for use in pharmaceutical formulations analysis and in vitro metabolism studies.
    Pasha MK; Muzeeb S; Basha SJ; Shashikumar D; Mullangi R; Srinivas NR
    Biomed Chromatogr; 2006 Mar; 20(3):282-93. PubMed ID: 16143964
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antiplatelet effects of a 600 mg loading dose of clopidogrel are not attenuated in patients receiving atorvastatin or simvastatin for at least 4 weeks prior to coronary artery stenting.
    Gorchakova O; von Beckerath N; Gawaz M; Mocz A; Joost A; Schömig A; Kastrati A
    Eur Heart J; 2004 Nov; 25(21):1898-902. PubMed ID: 15522468
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hydroxymethylglutaryl-coenzyme A reductase inhibitors induce apoptosis in human cardiac myocytes in vitro.
    Demyanets S; Kaun C; Pfaffenberger S; Hohensinner PJ; Rega G; Pammer J; Maurer G; Huber K; Wojta J
    Biochem Pharmacol; 2006 Apr; 71(9):1324-30. PubMed ID: 16540096
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Relationship between statin type and responsiveness to clopidogrel in patients treated with percutaneous coronary intervention: a subgroup analysis of the CILON-T trial.
    Suh JW; Cha MJ; Lee SP; Chae IH; Bae JH; Kwon TG; Bae JW; Cho MC; Rha SW; Kim HS
    J Atheroscler Thromb; 2014; 21(2):140-50. PubMed ID: 24140730
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.